Immunotherapy Advances : Impact Factor & More
eISSN: 2732-4303
Open AccessShare this on:
Key Metrics
SJR 
Q4Mathematics (all)
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Immunotherapy Advances
Immunotherapy Advances Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 2100 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Publication Details | |
| Publication Time | 7 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Immunotherapy Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Immunotherapy Advances
Turning the Tide: Harnessing Vaccines and Viruses to Fight Cancer
- 11 Nov 2025
- Immunotherapy Advances
89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatment
- 6 Oct 2025
- Immunotherapy Advances
Correction to: Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients
- 10 Sep 2025
- Immunotherapy Advances
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis
- 27 Aug 2025
- Immunotherapy Advances
Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8+ T-cell infiltration
- 28 Jul 2025
- Immunotherapy Advances
Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable in vitro model of exhaustion
- 11 Jun 2025
- Immunotherapy Advances
Turning the Tide: Harnessing Vaccines and Viruses to Fight Cancer
- 11 Nov 2025
- Immunotherapy Advances
89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatment
- 6 Oct 2025
- Immunotherapy Advances
Correction to: Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients
- 10 Sep 2025
- Immunotherapy Advances
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis
- 27 Aug 2025
- Immunotherapy Advances
Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8+ T-cell infiltration
- 28 Jul 2025
- Immunotherapy Advances
Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable in vitro model of exhaustion
- 11 Jun 2025
- Immunotherapy Advances
FAQs on Immunotherapy Advances
How many articles did Immunotherapy Advances publish last year? 
What is the SJR for Immunotherapy Advances?
Who is the publisher of Immunotherapy Advances?
